Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
JAZZ 
Jazz Pharmaceuticals PLC (JAZZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: JAZZ (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
18 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $188.01
Year Target Price $188.01
| 10 | Strong Buy |
| 6 | Buy |
| 2 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -14.69% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.47B USD | Price to earnings Ratio 14.52 | 1Y Target Price 188.01 |
Price to earnings Ratio 14.52 | 1Y Target Price 188.01 | ||
Volume (30-day avg) 18 | Beta 0.33 | 52 Weeks Range 95.49 - 148.06 | Updated Date 06/29/2025 |
52 Weeks Range 95.49 - 148.06 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 7.36 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.86% | Operating Margin (TTM) -2.9% |
Management Effectiveness
Return on Assets (TTM) 3.99% | Return on Equity (TTM) 12.25% |
Valuation
Trailing PE 14.52 | Forward PE 12.17 | Enterprise Value 9318807585 | Price to Sales(TTM) 1.59 |
Enterprise Value 9318807585 | Price to Sales(TTM) 1.59 | ||
Enterprise Value to Revenue 2.29 | Enterprise Value to EBITDA 7.46 | Shares Outstanding 60511000 | Shares Floating 59666753 |
Shares Outstanding 60511000 | Shares Floating 59666753 | ||
Percent Insiders 3.07 | Percent Institutions 101.94 |
Analyst Ratings
Rating 4 | Target Price 188.01 | Buy 6 | Strong Buy 10 |
Buy 6 | Strong Buy 10 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Jazz Pharmaceuticals PLC
Company Overview
History and Background
Jazz Pharmaceuticals was founded in 2003 in Ireland, focusing on developing pharmaceutical products to treat unmet medical needs. Initially focused on sleep disorders, it expanded through acquisitions and internal development.
Core Business Areas
- Sleep: Focuses on treatments for narcolepsy and idiopathic hypersomnia, including products like Xyrem and Xywav.
- Oncology: Develops and markets treatments for hematologic malignancies and solid tumors, including products like Defitelio and Zepzelca.
- Movement Disorders: Focuses on treatments for movement disorders like Parkinson's disease.
Leadership and Structure
Bruce Cozadd is the Chairman and CEO. The company has a structured management team across various functional areas like research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Market Share (%): 60
- Xywav/Xyrem: Treatment for narcolepsy. Xywav revenue was approximately $1.26B in 2023, and Xyrem revenue was approximately $209.4M. This is for US sales. Competitors include Avadel Pharmaceuticals with Lumryz.
- Epidiolex/Epidyolex: Treatment for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients one year of age and older. US revenue in 2023 was approximately $518M. Competitors include GW Pharmaceuticals (acquired by Jazz) and other anti-epileptic drugs.
- Market Share (%): 20
- Market Share (%): 10
- Zepzelca: Treatment for small cell lung cancer. Generated revenues of approximately $248M in 2023. Competitors include standard chemotherapy regimens and other targeted therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. Growth is driven by innovation, aging populations, and increasing healthcare spending.
Positioning
Jazz Pharmaceuticals is a specialty pharmaceutical company with a strong focus on sleep disorders and oncology. Its competitive advantages include established brands, a robust pipeline, and a strong market presence in its niche areas.
Total Addressable Market (TAM)
The TAM for sleep disorders and oncology is estimated to be billions of dollars. Jazz is well-positioned to capture a significant portion through its established products and ongoing research.
Upturn SWOT Analysis
Strengths
- Strong market position in sleep disorders
- Diversified product portfolio
- Established distribution network
- Experienced management team
- Strong R&D capabilities
Weaknesses
- Reliance on key products (Xyrem/Xywav)
- Exposure to generic competition
- High debt level
- Dependence on successful clinical trials
Opportunities
- Expansion into new therapeutic areas
- Acquisitions of complementary businesses
- Development of new formulations and indications
- Increased global presence
- Leveraging data analytics for improved patient outcomes
Threats
- Patent expirations
- Regulatory changes
- Competition from larger pharmaceutical companies
- Pricing pressures
- Clinical trial failures
Competitors and Market Share
Key Competitors
- Avadel Pharmaceuticals (AVDL)
- Supernus Pharmaceuticals (SUPN)
- Lundbeck (LUN.CO)
Competitive Landscape
Jazz faces competition from larger pharmaceutical companies and smaller biotech firms. Its competitive advantage lies in its specialized focus and established market presence.
Major Acquisitions
GW Pharmaceuticals
- Year: 2021
- Acquisition Price (USD millions): 7200
- Strategic Rationale: Expanded Jazz's neuroscience portfolio with the addition of Epidiolex, a cannabidiol (CBD) oral solution approved for the treatment of seizures associated with several rare epilepsies.
Growth Trajectory and Initiatives
Historical Growth: Jazz has experienced significant growth through acquisitions and product development. Revenue has increased steadily over the past decade.
Future Projections: Analysts project continued revenue growth driven by Xywav and its oncology portfolio. Future growth depends on the success of clinical trials and new product launches.
Recent Initiatives: Recent initiatives include acquisitions, pipeline development, and strategic partnerships to expand its therapeutic focus.
Summary
Jazz Pharmaceuticals is a specialized pharmaceutical company with strong positions in sleep disorders and oncology. Its strength lies in its established brands and diversified product portfolio. However, it faces challenges from generic competition and the need to develop new products. The GW Pharmaceuticals acquisition has bolstered its portfolio and pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Investor Relations
- Third-party financial data providers
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data are estimates and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jazz Pharmaceuticals PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2007-06-01 | Co-Founder, Chairman & CEO Mr. Bruce C. Cozadd | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2800 | Website https://www.jazzpharma.com |
Full time employees 2800 | Website https://www.jazzpharma.com | ||
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.